SU2C Scientific Advisors
Stand Up To Cancer’s Scientific Advisors ensure that your generous donations are being allocated to the most collaborative, innovative, and promising cancer research being done today. Our Advisors also oversee each grant recipient, to make sure that mandated research milestones are met, and that new treatments are on their way to our loved ones affected by cancer.
To learn more about out scientific advisors, please visit the links below.
Scientific Advisory Committee
Grants management and expert review for SU2C is conducted through the American Association for Cancer Research (AACR) via a rigorous, rapid and transparent process led by our “Blue Ribbon” Scientific Advisory Committee.
Chaired by Nobel Laureate Phillip A. Sharp, PhD, the Scientific Advisory Committee is comprised of highly accomplished scientists, physicians, and patient advocates, including:
Phillip A. Sharp, Ph. D., Chairperson, Institute Professor, MIT Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
Arnold J. Levine, Ph.D., Vice Chairperson, Professor, Institute for Advanced Study, Princeton, NJ
William G. Nelson, M.D., Ph.D., Vice Chairperson, Director, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Julian Adams, Ph.D., President of Research and Development, Infinity Pharmaceuticals, Inc., Cambridge, MA
Angelika Amon, Ph.D., Professor of Biology, MIT Koch Institute for Integrative Cancer Research, Massachussetts Institute Technology, Cambridge, MA
Kenneth C. Anderson, M.D., Kraft Family Professor of Medicine, Director, Lebow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
Frederick R. Appelbaum, M.D., Director, Clinical Research Division, Fred Hutchinson Cancer Research Center, Head, Division of Oncology, President, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, WA
Elizabeth H. Blackburn, Ph.D., Morris Herzstein, Professor, Department of Biochemistry and Biophysics University of California, San Francisco, San Francisco, CA
Richard B. Gaynor, M.D., Vice President, Clinical Development and Medical Affairs, Oncology Business Unit, Eli Lilly and Company, Indianapolis, IN
William N. Hait, M.D., Ph.D., Global Head, Janssen Research & Development, LLC, Raritan, NJ
Lee J. Helman, M.D., Scientific Director For Clinical Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Waun Ki Hong, M.D., Head, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX
Carl H. June, M.D., Program Director of Translational Research, Abramson Family Cancer Research Institute, Abramson Cancer Center of University of Pennsylvania, Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
William G. Kaelin, Jr., M.D., Professor, Dana-Farber Cancer Institute, Boston, MA
Michael B. Kastan, M.D., Ph.D., Executive Director, Duke Cancer Institute, Durham, NC
Richard D. Kolodner, Ph.D., Professor of Medicine, University of California, San Diego Ludwig Institute for Cancer Research, La Jolla, CA
Guillermina (Gigi) Lozano, Ph.D., Chairman & Professor, Department of Genetics, UT MD Anderson Cancer Center, Houston, TX
Thomas J. Lynch, Jr., M.D., Director, Yale Cancer Center, Physician-in-Chief, Smillow Cancer Hospital at Yale-New Haven Hospital, Richard and Jonathan Sackler Professor of Internal Medicine, Yale University, New Haven, CT
Tak W. Mak, Ph.D., Director, Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada
Cecil B. Pickett, Ph.D., President, Research and Development (retired), Biogen Idec, Cambridge, MA
Ellen V. Sigal, Ph.D.*, Chairperson and Founder, Friends of Cancer Research, Washington, DC
David A. Tuveson, M.D., Ph.D., Professor, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
* Denotes Patient Advocate committee members selected by the SU2C Advocate Advisory Council
The Executive Management Committee (EMC) for SU2C serves an advisory role to the Executive Leadership Committee (ELC) to support them in their cancer research philanthropy, particularly in its scientific aspects, including: setting priorities, determining preferred funding models, identifying new opportunities and evaluating the success of the program. Committee members include noted leaders in clinical and translational cancer research, oncology and patient advocacy.
The six members of the Management Committee are:
John Glaspy, M.D., Chairperson, Professor of Medicine in the UCLA Dept of Medicine, Division of Hematology and Oncology
Andy Conrad, Ph.D, CEO, Google Life Sciences
Sue Desmond-Hellman, M.D., M.P.H. (Emeritus), Chief Executive Officer, Bill & Melinda Gates Foundation
Raymond N. DuBois, M.D., Ph.D., Executive Director of the Biodesign Institute, Arizona State University
Kathy Giusti, co-founder of the Multiple Myeloma Research Foundation (MMRF) and former pharmaceutical industry executive
Lee Nadler, M.D., Virginia and D.K Ludwig Professor of Medicine
Dean for Clinical and Translational Research at Harvard Medical School, Director of Harvard Catalyst and SVP for Experimental Medicine at the Dana-Farber Cancer Institute
American Association for Cancer Research (AACR)
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 97 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with over 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.